As messengers bridging the innate and adaptive immune system, the conventional tissue-resident DC (cDC) acts as sentinels in secondary lymphoid organs and other tissues for antigen capture and presentation. The MutuDCTlr9-/- cell line is an immortalized splenic CD8alpha+ subset (CD11chigh,B220-,DEC205+,CD24high,CD11b-) of conventional dendritic cells derived from the TLR9 knockout CD11c:SV40LgT transgenic mice. The MutuDCTlr9-/- cell line retains response to TLR ligands such as PolyIC (TLR3-L) and to a lesser extent LPS (TLR4-L) but not CpG (TLR9-L). Like the Wild-type MutuDC cells (Cat. No. T0528), these cells are capable of presenting antigen in the context of both MHC-I and MHC-II, including direct antigen presentation and cross-presentation of cell-associated antigens. Together with TLR3 knockout (Cat. No. T3034) and Ifnar1 knockout (Cat. No. T3036) MutuDC, these dendritic cell lines provide a powerful tool in vaccine science and immunotherapy, particularly in strategizing target antigens to CD8alpha+ subset.
Cell Type
Drug Discovery Cells
Disclaimer
1. For for-profit organizations and corporations, please contact [email protected] for pricing of this item. 2. Sale of this item is subjected to the completion of a Material Transfer Agreement (MTA) by the purchasing individual/institution for each order. If you have any questions regarding this, please contact us at [email protected]. 3. All test parameters provided in the CoA are conducted using abm's standardized culture system and procedures. The stated values may vary under the end-user's culture conditions. Please verify that the product is suitable for your studies by referencing published papers or ordering RNA (0.5 mug, Cat.# C207, $450.00) or cell lysate (100 mug, Cat.# C206, $600.00) to perform preliminary experiments, or alternatively use our Gene Expression Assay Service (Cat# C138). All sales are final. 4. We recommend live cell shipments for ease of cell transfer and this option can be requested at the time of ordering. Please note that the end-user will need to evaluate the feasibility of live cell shipment by taking into account the final destination's temperature variation and its geographical location. In addition, we thoroughly test our cell lines for freeze-thaw recovery. If frozen cells were received and not recovered in your lab under the exact, specified conditions (using recommended culture vessel, media, additional supplements, and atmospheric conditions), a live cell replacement is possible at a cost (plus shipping). 5. All of abm's cell biology products are for research use ONLY and NOT for therapeutic/diagnostic applications. abm is not liable for any repercussions arising from the use of its cell biology product(s) in therapeutic/diagnostic application(s). Please contact a technical service representative for more information. 6. abm makes no warranties or representations as to the accuracy of the information on this site. Citations from literature and provided for informational purposes only. abm does not warrant that such information has been shown to be accurate. 7. abm warrants that cell lines shall be viable upon initiation of culture for a period of thirty (30) days after shipment and that they shall meet the specifications on the applicable abm Material Product Information sheet, certificate of analysis, and/or catalog description. Such thirty (30) day period is referred to herein as the "Warranty Period."
The base medium for this cell line is PriGrow V available at abm (TM015). To make the completed growth medium, add the following components to the base medium: 10% decomplemented fetal calf serum (PAN biotech; P40-37500), 50 µM ?-mercaptoethanol, 1% HEPES, and Penicillin/Streptomycin Solution (G255) to a final concentration of 1%. Stimulation can be performed using CpG (2 mM) or LPS (5 µg/ml). Carbon dioxide (CO2): 5%, Temperature: 37.0°C. IMPORTANT: This cell line is very sensitive to FBS batches. We strongly recommend end users to use FBS obtained from PAN biotech.
Quality Control
1) Direct antigen presentation and cross-antigen presentation were evaluated by the MHC-I (SIINFEKL/OT-I ) and MHC-II (OVA323-339/OT-II) restricted systems; 3) proteome profile and surface markers assessed by RT-PCR; RT-PCR; 3) IL-12 cytokine secretion analyzed using ELISA ; 4) Response to PAMP stimulation evaluated by functional assays.
Reviews of TLR8-NF-kappaB Stable Reporter 293 Cell Line